Transcranial Pulse Stimulation

NEUROLITH Transcranial Pulse Stimulation (TPS®) is a new state of the art .treatment for Alzheimer’s Disease and mild to moderate dementia.

More than 850,000 people in the UK are living with Alzheimer’s and dementia and this number is growing fast thanks to an ageing population as well as other factors. It’s believed that 1 in 3 people born now will develop this disease.

neurolith big product image

System at a Glance

  • BodyTrack® software
  • 3D Camera with patient and handpiece position detection
  • Calibration probe & tracking glasses with markers
  • TPS handpiece with markers – ergonomic design to minimize hand fatigue

Quick and effective easy treatments

Just six 30 minute treatments over 2 weeks can improve Alzheimer’s and mild to moderate dementia by 10 points on the CERAD scale.

Stimulates Deep Cerebral Regions of the Brain

NEUROLITH® uses Transcranial Pulse Stimulation (TPS®) technology, consisting of short acoustic pulses with an ultrasound frequency range that permits a well-focused stimulation of the brain at a depth of up to 8 cm. NEUROLITH® received medical CE in December 2018.

Clinically Proven to Significantly Improve Cognitive Abilities

Studies show that the transcranial pulse stimulation not only maintains the cognitive abilities of patients with mild to moderate Alzheimer’s disease, but even improves them significantly. Data also shows that the improvements last for at least 3 months after a course of TPS®. TPS® on average improved cognition by 10 points on the CERAD scale.

Patients and close relatives also reported noticeable improvements in memory and verbal communication, which subsequently and indirectly led to an increase in social interaction. Some patients even reported an improved sense of direction that enabled them to do their daily tasks independently and safely find their way home afterwards.

How does it treat and improve Alzheimer’s Disease?

TPS® induces mechanotransduction, stimulating growth factors, primarily VEGF3,4. This not only improves cerebral blood flow, but also promotes the formation of new blood vessels (angiogenesis) and nerve regeneration. In addition it causes the release of nitric oxide (NO)5, which leads to direct vasodilation and improved blood circulation. Transcranial Pulse Stimulation (TPS®) enables targeted stimulation of the cerebral regions.

transcranial pulse stimulation for Alzheimer's

Biological Effects

  • Mechanotransduction(6)
  • Increase in cell permeability (7)
  • Stimulation of mechanosensitive ion channels (6)
  • Release of nitric oxide (NO)5, which leads to vasodilation, increased metabolic activity and angiogenesis and has an anti-inflammatory effect
  • Stimulation of vascular growth factors (VEGF)(3,4)
  • Stimulation of BDNF8
  • Migration and differentiation of stem cells (4,6)
neurolith product image

Transcranial pulse stimulation stimulates deep cerebral regions, targeting as deep as 8 cm into the brain tissue

Is Transcranial Pulse Stimulation (TPS®) Safe?

Neurolith TPS® is very safe, thanks to the short duration of the TPS® stimulation, heating of the tissue is prevented. TPS® treatment is performed directly through the skull, non-invasively. The patient remains awake during the treatment in a comfortable seated position. More than 1800 treatments have been performed using the NEUROLITH® TPS system.

The Advantages of TPS®

Pulses stimulate deep cerebral regions of the brain up to 8cm, these are applied directly to the required treatment areas for maximum clinical effectiveness. The TPS® treatment has been shown to significantly improve CERAD test performance and to reduce Beck’s depression index in patients with mild to moderate dementia.

  • 30 minutes per session in outpatient clinics
  • 6 treatment sessions over 2 weeks
  • A Painless treatment
  • No side effects
  • Personalised treatments based on MRI data
  • Adjuvant cognitive training not required
  • Non-invasive
  • No need to shave the hair
  • The patient can remain mobile in a comfortable seated position during treatment
  • Focused stimulation of deep cerebral regions
  • Personalised 3D visualisation of patient’s head
  • 3D infrared camera system for precise cerebral tracking
  • USB interface for MRI data import
  • Patient database
neurolith brain diagram

BodyTrack® – Live treatment tracking

The BodyTrack® live tracking technology enables automatic visualisation of the treated regions. Personalised patient MRI data allows specific characteristics of the patient’s brain to be taken into account. Every time the handpiece position changes, the visualisation of the target regions in the loaded MRI scans is automatically updated, energy is then applied exactly where is needed, highlighted in colour for ease of use.

neurolith screen examples

The advantages of the TPS® BodyTrack® software

  • Uses the patient’s own personalised MRI data
  • Visualisation of MRI data in 3 planes (axial, coronal, sagittal)
  • Coloured visualisation of the treatment region
  • Real-time visualisation of TPS® pulse distribution
  • Continuous visualisation and documentation of the energy applied and of treatment progress


3 – Yahata, K. et al.: Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury, J Neurosurg Spine, Vol. 25(6), Pages 745–755, 2016

4 – Hatanaka, K. et al.: Molecular mechanisms of the angiogenic effects of low-energy shock wave therapy: roles of mechanotransduction, Am J Physiol Cell Physiol, Vol. 311(3), C378–C385, 2016

5 – Mariotto, S. et al.: Extracorporeal shock waves: From lithotripsy to anti-inflammatory

action by NO production, Nitric Oxide, Vol. 12(2), 89–96, 2005

6 – D´Agostino, M. C. et al.: Shock wave as biological therapeutic tool: From mechanical stimulation to recovery and healing, through mechanotransduction, Int J Surg., Dec. 24(Pt B), 147-153, 2015

7 – López-Marín, L. M. et al.: Shock wave–induced permeabilization of mammalian cells, Phys Life Rev., 26-27:1-38, 2018

8- Wang, B. et al.: Low-Intensity Extracorporeal Shock Wave Therapy Enhances Brain-Derived Neurotrophic Factor Expression through PERK/ATF4 Signaling Pathway, Int J Mol Sci., Feb 16;18(2). pii: E433, 2017

Other Focused Shockwaves Systems

Get in Touch

  • This field is for validation purposes and should be left unchanged.